FDA panel rejects Sanofi-Aventis weight loss drug

Share this article:

An FDA advisory panel today unanimously rejected approval of Sanofi-Aventis' weight-loss drug rimonabant after hearing testimony that the drug increases the risk of suicidal behavior.

The panel's finding makes it unlikely that the FDA will grant approval for the drug. The agency usually follows the advice of its advisory panels, although it is not required to do so.

The FDA is scheduled to make a final decision on rimonabant by July 27.

The company proposes selling the drug under the brand name Zimulti. Rimonabant is already sold in Europe as Acomplia.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...